2Mofidi R, Duff MD, Wigmore SJ, et al. Association between early systemie inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis [J]. Br J Surg, 2006, 93 (6) :738-744.
3Bhatia M, Neoptolemos JP, Slavin J. Inflammatory mediators as therapeutic targets in acute pancreatitis [J]. Curr Opin Investig Drugs, 2001, 2 (4):496-501.
6Oruc N, Ozutemiz AO, Yukselen V, et al. Infliximab: A new therapeutic agent in acute pancreatitis? [J] . Pancreas, 2004, 28 (1) :1-8.
7Fantini L, Tomassetti P, Pezzilli R. Management of acute pancreatitis: current knowledge and future perspectives [J]. World J Emerg Surg, 2006, 1: 16.
8Grewal HP, Mohey el Din A, Gaber L, et al. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody [J] . Am J Surg, 1994, 167 (1) :214-218.
9Triantafillidis JK, Cheracakis P, Hereti IA, et al. Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment [J]. Am J Gastroenterol, 2000, 95 (11) : 3334-3336.
4Miller BJ, Henderson A, Strong RW, et al.Necrotizing pancreatitis: operating for life.World J surg,1994,18:906-910.
5Yekebas EF, Eisenberger CF, Ohnesorge H, et al.Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis.Crit Care Med,2001,29:1423-1430.
6Andrulli A, Perri F, Annese V. Guidelines for treatment of acute pancreatitis. Gut, 1999,44:579-580.
7Kramer P, Wigger W, Rieger J,et al. Arteriovenous haemofiltration : a new and simple method for treatment of over-hydrated patients resistant to diuretics.Klin Wochenschr,1977,55:1121-1122.
8Kamijo Y, Wakabayashi Y, Shirasaki K, et al. Continuous hemofiltration removes circulatory cytokines and improves multiple organ dysfunction syndrome following severe acute pancreatitis-A case report. Japan J Gastroenterol,1995,92:1013-1017.
4[2]Bone RC,Balk RA,Cerra FB,et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.The ACCP/SCCM Consensus Conference Committee American College of Chest Physician/Society of Critical Care Medicine.Chest,1992,101:1644-1645.
5[4]Sath A,Shimosegawa T,Fujita M,et al.Inhibition of nuclear factor kappa B activating improves the survival of rat with traurocholate pancreatitis.Gut,1999,44(2):253-258.
6[5]Karne S,Gorelick FS.Etiopathogenesis of acute panereatitis.Surg Clin North Am,1999,79:699-710.
7Bhatia M, Neoptolemos JP, Slavin J. Inflammatory mediators as therapeutic targets in acute pancreatitis [ J ] . Curr Opin Investig Drugs, 2001, 2 (4) : 496-501.
8Oruc N, Ozutemiz AO, Yukselen V, et al. Infliximab: A new therapeutic agent in acute pancreatitis? [ J] . Pancreas, 2004, 28 ( 1 ) : 1-8.
9Fantini L, Tomassetti P, Pezzilli R. Management of acute pancreatitis: current knowledge and future perspectives [J] . World J Emerg Surg, 2006, 23 (1) : 16.
10Triantafinidis JK, Cheracakis P, Hereti IA, et al. Acute idiopathic pancreatitis complicating active Crohn' s disease: favorable response to infliximab treatment [ J ] . Am J Gastroenterol, 2000, 95 (11) : 3334-3336.
